Progress in treating advanced non-small cell lung cancer<\/h3>\n
![\"Dr.](\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/rru-aggarwal.png\")
<\/p>\n
Dr. Charu Aggarwal, the 2022 Cancer.Net Associate Editor for Lung Cancer<\/a>, discusses 3 studies in non-small cell lung cancer (NSCLC)<\/a>. First, she discusses findings from a phase 1\/2a clinical trial<\/a> that was evaluating a new drug called CLN-081 for treating people with advanced NSCLC with an EGFR<\/i> exon 20 insertion mutation<\/a>. [3:53] Next, Dr. Aggarwal describes the phase 1\/2 KRYSTAL-1 clinical trial<\/a>, which was studying the targeted therapy drug adagrasib for people with advanced NSCLC with a KRAS<\/i> G12C mutation. [5:06] Finally, she discusses the phase 2 Lung-MAP clinical trial<\/a>, which was testing whether the combination of the immunotherapy<\/a> drugs pembrolizumab (Keytruda) and ramucirumab (Cyramza) helped people with advanced NSCLC if initial immunotherapy did not stop the cancer. [7:28]<\/p>\n Dr. Christopher Flowers, the 2022 Cancer.Net Associate Editor for Lymphoma<\/a>, discusses several studies in treating 2 subtypes of non-Hodgkin lymphoma<\/a>. First, he discusses 2 studies in mantle cell lymphoma<\/a>. The first study, called the phase 3 SHINE clinical trial<\/a>, was evaluating whether adding the immunotherapy drug ibrutinib (Imbruvica) to standard treatment slowed mantle cell lymphoma from growing or spreading in people aged 65 or older. [12:01] The second study, which was a 3-year follow-up of the phase 2 ZUMA-2 clinical trial<\/a>, observed whether a type of CAR T-cell therapy<\/a> called brexucabtagene autoleucel (Tecartus) slowed the cancer from growing or spreading in people with recurrent or refractory mantle cell lymphoma. [13:25]<\/p>\n Next, Dr. Flowers discusses 3 studies in diffuse large B-cell lymphoma (DLBCL)<\/a>. The first study, called the phase 3 POLARIX clinical trial<\/a>, was studying whether a treatment called pola-R-CHP, which is the combination of the targeted therapy drugs polatuzumab vedotin (Polivy) and rituximab (Rituxan) with the chemotherapy drugs cyclophosphamide (available as a generic drug), doxorubicin (available as a generic drug), and prednisone (multiple brand names), helped slow cancer growth better than the standard treatment in people with double-expressor DLBCL, which is a type of aggressive lymphoma. [14:26] The next study was a phase 2 clinical trial<\/a> that evaluated the immunotherapy drug glofitamab for treating people with recurrent or refractory DLBCL. [16:22] Last, Dr. Flowers discusses a phase 1\/2 clinical trial<\/a> that was observing whether adding the immunotherapy drug epcoritamab to standard treatment was safe to use for people with newly diagnosed DLBCL. [17:00]<\/p>\n Dr. Daniel A. Mulrooney, the 2022 Cancer.Net Associate Editor for Pediatric Cancers<\/a>, discusses 4 studies: a study in Ewing sarcoma and 3 studies in neuroblastoma. First, he discusses the phase 3 rEECur clinical trial<\/a>, which was studying whether the high-dose chemotherapy ifosfamide (Ifex) lengthened the amount of time until the cancer came back or got worse in people with recurrent or refractory Ewing sarcoma<\/a> compared to 3 other commonly prescribed chemotherapy treatments. [20:15]<\/p>\n Next, Dr. Mulrooney discusses 3 studies in neuroblastoma<\/a>. The first study, called the phase 2 BEACON clinical trial<\/a>, was studying whether adding the immunotherapy drug dinutuximab beta (Qarziba) to chemotherapy shrunk the tumors or delayed tumor growth in people with recurrent or refractory neuroblastoma. [24:21] Then, he discusses a pilot study from the Children\u2019s Oncology Group (COG)<\/a> that studied adding immunotherapy to chemotherapy earlier in the treatment plan for high-risk neuroblastoma. [25:28] Finally, he discusses a retrospective study from COG<\/a> observing how race, ethnicity, and socioeconomic status<\/a> impact survival in children with high-risk neuroblastoma. [27:11]<\/p>\n Disclosure information for Dr. Aggarwal, Dr. Flowers, and Dr. Mulrooney can be found in their individual biographies linked to in the paragraphs above.<\/p>\n Was this podcast useful?<\/i><\/b> Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript<\/a> is also available. For more information, visit the <\/i>Cancer.Net podcast page<\/i><\/a>.<\/span><\/i><\/p>\n Cancer.Net podcasts are edited for length and content. <\/i><\/p>\nNew research in treating subtypes of non-Hodgkin lymphoma<\/h3>\n
![\"Dr.](\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/rru-flowers.png\")
<\/p>\nStudies in childhood Ewing sarcoma and neuroblastoma<\/h3>\n
![\"Dr.](\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/rru-mulrooney.jpg\")
<\/p>\n